SLC3A2 and neoplasm: Recently studies have gradually revealed that the biological pathway of ferroptosis has a critical role in the immunotherapy combination therapy of tumors, where CD8+ T cell activity is activated during tumor immunotherapy, whereas CD8+ T cells down-regulate the expression of the two subunits of the glutamate-cystine antagonist system xc-, SLC3A2 and SLC7A11, through the release of interferon-γ, which promotes tumor cell lipid peroxidation and ferroptosis30.